# A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)

> **NCT06926868** · PHASE2,PHASE3 · RECRUITING · sponsor: **Bristol-Myers Squibb** · enrollment: 500 (estimated)

## Conditions studied

- Breast Neoplasms

## Interventions

- **DRUG:** Iza-bren
- **DRUG:** Nab-paclitaxel
- **DRUG:** Paclitaxel
- **DRUG:** Capecitabine
- **DRUG:** Carboplatin
- **DRUG:** Gemcitabine

## Key facts

- **NCT ID:** NCT06926868
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-09-11
- **Primary completion:** 2028-03-13
- **Final completion:** 2030-05-15
- **Target enrollment:** 500 (ESTIMATED)
- **Last updated:** 2026-04-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06926868

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06926868, "A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT06926868. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*